Exploring magnesium myristate for its dual functionality as a binder and lubricant in the formulation of tablet
Purpose: To explore 'magnesium myristate' for its dual functionality as a lubricant and binder in the formulation of tablets. Methods: Using (DoE), tablet formulations using magnesium myristate and conventional excipients (magnesium stearate and PVP K30) were developed by wet granulation technique. The prepared granules and formulated tablets were evaluated for pre- and post-compression parameters, respectively. Results: Magnesium myristate exhibited excellent flow properties. The optimized formulations containing magnesium myristate exhibited increased hardness and in vitro drug release in comparison to conventional excipients. f2 similarity index for in vitro drug release showed no significant variations with optimized formulations and with the marketed formulations. Conclusion: Magnesium myristate shows a promising replacement for conventional excipients as both a lubricant and binder in tablet formulation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Therapeutic delivery - 15(2024), 4 vom: 18. März, Seite 253-266 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pockle, Rachana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Conventional excipients |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4155/tde-2023-0101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369106768 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369106768 | ||
| 003 | DE-627 | ||
| 005 | 20240318234525.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2023-0101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM369106768 | ||
| 035 | |a (NLM)38420754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pockle, Rachana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Exploring magnesium myristate for its dual functionality as a binder and lubricant in the formulation of tablet |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Purpose: To explore 'magnesium myristate' for its dual functionality as a lubricant and binder in the formulation of tablets. Methods: Using (DoE), tablet formulations using magnesium myristate and conventional excipients (magnesium stearate and PVP K30) were developed by wet granulation technique. The prepared granules and formulated tablets were evaluated for pre- and post-compression parameters, respectively. Results: Magnesium myristate exhibited excellent flow properties. The optimized formulations containing magnesium myristate exhibited increased hardness and in vitro drug release in comparison to conventional excipients. f2 similarity index for in vitro drug release showed no significant variations with optimized formulations and with the marketed formulations. Conclusion: Magnesium myristate shows a promising replacement for conventional excipients as both a lubricant and binder in tablet formulation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a conventional excipients | |
| 650 | 4 | |a dual functionality | |
| 650 | 4 | |a magnesium myristate | |
| 650 | 4 | |a similarity index | |
| 650 | 4 | |a tablet formulation | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Magnesium |2 NLM | |
| 650 | 7 | |a I38ZP9992A |2 NLM | |
| 650 | 7 | |a Myristates |2 NLM | |
| 650 | 7 | |a Lubricants |2 NLM | |
| 650 | 7 | |a Tablets |2 NLM | |
| 700 | 1 | |a Masareddy, Rajashree |e verfasserin |4 aut | |
| 700 | 1 | |a Bambulkar, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Rishabh |e verfasserin |4 aut | |
| 700 | 1 | |a Kiran, Sai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic delivery |d 2010 |g 15(2024), 4 vom: 18. März, Seite 253-266 |w (DE-627)NLM203937082 |x 2041-6008 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:4 |g day:18 |g month:03 |g pages:253-266 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4155/tde-2023-0101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 4 |b 18 |c 03 |h 253-266 | ||